Screening also prevents rare types of cervical cancer
[PRESS RELEASE 2019-04-04] Rare types of cervical cancer can be effectively prevented with screening, a comprehensive study of identified cases of rare cervical cancer over a ten-year period in Sweden concludes. The study was conducted by researchers at Karolinska Institutet and is published in The BMJ.
The main aim of cervical screening is to discover and treat lesions that could otherwise become cancerous. There has been a nationwide cervical screening programme in Sweden since the 1960s.
While earlier studies have shown that screening reduces the risk of the most common types of cervical cancer, little has been known about the link between screening and the risk of rarer types of the cancer.
This has now been investigated by researchers at Karolinska Institutet in a study published in The BMJ, in which they investigated all Swedish cases of invasive cervical cancer from 2002 to 2011, identified using the National Swedish Cancer Registry. Of these over 4,200 cases, 338 were identified as not belonging to the most common types of cervical cancer (squamous epithelial cancer and adenocarcinoma).
The researchers randomly selected 30 age-matched controls from the Swedish female population for each case and then calculated the risk of so-called adenosquamous cell carcinoma and other rare types of cervical cancer, in relation to being screened.
The results show that women who had participated in the screening program on the last two occasions they were invited, were over 75 per cent and 65 per cent less likely to have developed adenosquamous and other rare types of cervical cancer, respectively, than women who had not been screened.
“This shows that rare types of cervical cancer can be effectively prevented through screening,” says co-author Professor Pär Sparén at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, guarantor of the study.
The decrease in risk was greater for women who had been screened twice instead of just once in the past two screening periods.
High-risk human papillomavirus (HPV) is the leading cause of cervical cancer and was identified by the study in 70 per cent of the rare tumours in which such typing was possible. The most common type was HPV 18, followed by HPV 16.
This suggests, according to the researchers, that most cases of rare cervical cancer can be prevented by HPV vaccination.
The study reported no difference in the effect of screening between women with and without high-risk HPV in their tumours.
The researchers note that continued monitoring of these rare types of cervical cancer is necessary when the screening of cervical cancer now is to be done by HPV testing instead of primary cytological analysis of cell samples.
The research was financed by the Swedish Foundation for Strategic Research, the Swedish Research Council, the China Scholarship Council and the Centre for Research and Development at Uppsala University/Region Gävleborg. Co-author Joakim Dillner has received grants from Roche and Genomica for research on HPV tests.
Publication: “Cervical screening and risk of adenosquamous and rare types of invasive cervical carcinoma: a population-based nested case-control study”. Jiayao Lei, Bengt Andrae, Alexander Ploner, Camilla Lagheden, Carina Eklund, Sara Nordqvist Kleppe, Jiangrong Wang, Fang Fang, Joakim Dillner, K. Miriam Elfström and Pär Sparén. The BMJ, online 4 April 2019, doi: 10.1136/bmj.l1207.
Karolinska Institutet is one of the world’s leading medical universities. Its vision is to significantly contribute to the improvement of human health. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.